FDG PET/CT IMAGING IN CANINE CANCER PATIENTS
Article first published online: 26 OCT 2010
© 2010 Veterinary Radiology & Ultrasound
Veterinary Radiology & Ultrasound
Volume 52, Issue 2, pages 201–206, March/April 2011
How to Cite
HANSEN, A. E., MCEVOY, F., ENGELHOLM, S. A., LAW, I. and KRISTENSEN, A. T. (2011), FDG PET/CT IMAGING IN CANINE CANCER PATIENTS. Veterinary Radiology & Ultrasound, 52: 201–206. doi: 10.1111/j.1740-8261.2010.01757.x
- Issue published online: 9 MAR 2011
- Article first published online: 26 OCT 2010
- Received June 10, 2010; accepted for publication September 9, 2010.
2-Deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography (FDG PET/CT) is becoming increasingly available as an imaging modality in veterinary medicine. The purpose of this study was to report semiquantitative standard uptake values (SUV) of malignant and nonmalignant tissues and organs in canine cancer patients. FDG PET/CT was performed in 14 dogs including, nine mesenchymal tumors, four carcinomas, and one incompletely excised mast cell tumor. A generally higher FDG uptake was observed in carcinomas relative to sarcomas. Maximum SUV of carcinomas ranged from 7.6 to 27.0, and for sarcomas from 2.0 to 10.6. The FDG SUV of several organs and tissues, including regional brain uptake is reported, to serve as a reference for future FDG PET studies in canine cancer patients. Several potential pitfalls have been recognized in interpretation of FDG PET images of human patients, a number of these were also observed in this study.